ArticleThe Pan African medical journal2025
Public perception and correlates of Mpox vaccine acceptability in northern Nigeria: a mixed methods study.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants of Mpox vaccine uptake and hesitancy among healthcare workers in Port Harcourt, Nigeria.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: little has been documented about public perceptions and acceptance of the mpox vaccine in endemic countries, such as Nigeria. We assessed public awareness, risk perception, and correlates of vaccine acceptability in urban Kano, Nigeria. Methods: employing a mixed methods design, structured questionnaires were administered to 415 adults in metropolitan Kano. The data were analyzed using binary logistic regression and the framework approach. Results: nearly all respondents (99.0%, n=411) have heard about mpox, but only one-half (49.9%, n=207) of the respondents were willing to take the mpox vaccine. Female respondents were 33% less likely to accept mpox vaccination (adjusted odds ratio, aOR=0.67, 95% confidence interval CI: 0.42-0.92). Respondents who perceived mpox as a severe disease (aOR = 1.37, 95% CI, 1.12-2.20), those who self-assessed as high risk (aOR=2.10, 95% CI, 1.10-7.46) or who perceived vaccines as protective (aOR=8.99, 95% CI,1.79-45.30) were more likely to accept the vaccine. There were three-fold increased odds of accepting the mpox vaccine among participants who received vaccinations during adulthood (aOR=3.58, 95% CI, 2.20-5.82), and those who were vaccinated against COVID-19 (aOR=2.86, 95% CI, 1.45-5.64). Reasons for vaccine hesitancy include vaccine safety concerns, low-risk perception, mistrust of authorities and pharmaceutical companies, the newness of the vaccine, hurried introduction, fear of side effects, and perceived misplaced government priorities. Conclusion: Mpox awareness was near-universal in our study population, but mpox vaccine acceptance was sub-optimal. mpox vaccine acceptance was influenced by sociodemographic (gender, ethnicity, religion), vulnerability (perceived risk, perceived effectiveness of vaccines), and health behavior-related (COVID-19 vaccination status) factors. Risk communication, community engagement, and socio-behavioral interventions could help build public confidence and boost vaccine acceptance in similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.